BioWorld Science - Articles

Endocrine/Metabolic

Genescience presents new GHSR agonists for growth hormone deficiency

Nov. 25, 2022

Genescience Pharmaceuticals Co. Ltd. has divulged indoline-containing spiro derivatives acting as growth hormone secretagogue receptor (GHSR) agonists reported to be useful for the treatment of growth hormone deficiency.

3D illustration of liver and photomicrograph showing triglyceride fat accumulated in liver cells.

Endocrine/Metabolic

LXR inverse agonist TLC-2716 reduces lipogenesis in preclinical models

Nov. 23, 2022

The liver X receptor (LXR) is a nuclear hormone receptor that is one of the most important regulators of cholesterol homeostasis and plays a key role in triglyceride (TG) regulation. Researchers from Orsobio Inc. and Phenex Pharmaceuticals AG have presented preclinical data on TLC-2716, a potent, small-molecule LXR inverse agonist for the treatment of lipid disorders.

Endocrine/Metabolic

TLC-6740 demonstrates multiple metabolic benefits in vivo

Nov. 22, 2022

Scientists from Orsobio Inc. and affiliated organizations have described preclinical data for the novel liver-targeted mitochondrial protonophore TLC-6740, being developed for the treatment of metabolic disease. In vitro, mild mitochondrial uncoupling caused by TLC-6740 had pleotropic metabolic benefits in multiple cell lines. TLC-6740 increased mitochondrial potential, oxygen consumption rate and tricarboxylic acid (TCA) cycle flux, and it also inhibited de novo lipogenesis with EC50 values of 6.9 µM.

Endocrine/Metabolic

Gilead Sciences describes new GLP-1R agonists

Nov. 18, 2022

Gilead Sciences Inc. has synthesized carboxy-benzimidazoles acting as glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of arthritis, diabetes, eating disorders, macular degeneration, myocardial infarction, nonalcoholic steatohepatitis, sleep apnea and Parkinson's disease, among others.

Endocrine/Metabolic

Novel activators of AMPK show efficacy in models of type 2 diabetes

Nov. 16, 2022

Researchers from Rigel Pharmaceuticals Inc. have reported the discovery of indirect activators of AMPK as potential candidates for the treatment of type 2 diabetes.

Obesity, fat cell research concept image

Endocrine/Metabolic

Rose Biosciences to take forward MCW discovery for obesity

Nov. 15, 2022

Medical College of Wisconsin (MCW) has announced the founding of Rose Biosciences, a biotech company pioneering a new approach to obesity treatment based on a discovery at MCW.

Mitochondria long way from the nucleus and in need of closer sources of proteins

Neurology/Psychiatric

Neuroscience 2022: ‘Strawberries’, ‘cabbages,’ fats in neuronal mitochondria

Nov. 15, 2022

By Mar de Miguel

Neurons are specialized cells with a high metabolic demand to fulfill their function, survive or keep a healthy half-life. In this sense, the anabolism and catabolism of proteins and lipids could be associated to different neurodegenerative diseases. At the 2022 annual meeting of the Society for Neuroscience, scientists reported the latest discoveries on neuron metabolic needs at a session on 'Powering Thoughts: The Regulation of Neuronal Energy Metabolism and Mitochondria.'

Cancer

From mouse to man, UBR2 is target in cancer cachexia

Nov. 14, 2022

By W. Todd Penberthy

Investigators working at University of Texas Health Science Center, Houston, have discovered that the ubiquitin ligase UBR2 is up-regulated and sufficient for targeting the myosin heavy chain protein for the degradation characteristic of cancer cachexia. UBR2 knockout or pharmacological inhibition could prevent cachexia in mice. Confirmatory observations were noted in cancer cachexia patient-derived tissues.

Endocrine/Metabolic